| Name | Mucin-1 | ||
| UniProt ID | MUC1_HUMAN | ||
| Gene Name | MUC1 | ||
| Gene ID | 4582 | ||
| Synonyms |
MUC1, ADMCKD, ADMCKD1, ADTKD2, CA_15-3, CD227, Ca15-3, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X, MUC1/ZD, PEM, PEMT, PUM
|
||
| Sequence |
MTPGTQSPFFLLLLLTVLTATTAPKPATVVTGSGHASSTPGGEKETSATQRSSVPSSTEK
NAVSMTSSVLSSHSPGSGSSTTQGQDVTLAPATEPASGSAATWGQDVTSVPVTRPALGST TPPAHDVTSAPDNKPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDNRPALGST APPVHNVTSASGSASGSASTLVHNGTSARATTTPASKSTPFSIPSHHSDTPTTLASHSTK TDASSTHHSTVPPLTSSNHSTSPQLSTGVSFFFLSFHISNLQFNSSLEDPSTDYYQELQR DISEMFLQIYKQGGFLGLSNIKFRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASR YNLTISDVSVSDVPFPFSAQSGAGVPGWGIALLVLVCVLVALAIVYLIALAVCQCRRKNY GQLDIFPARDTYHPMSEYPTYHTHGRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPAVAAT SANL |
||
| Pathway Map | MAP LINK | ||
| T.C. Number | 1.A.4.2.10; 2.A.3.8.18; 8.A.23.1.64; 8.A.77.1.2; 9.B.452.1.1 | ||
| KEGG ID | hsa4582 | ||
| TTD ID | T18779 | ||
| Pfam | PF01390; PF16959; PF17410 | ||
| Pair Name | Solamargine, Sorafenib | |||
| Phytochemical | Solamargine | |||
| Drug | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Regulate Info | Down-regulation | Mucin-1 | Expression | |
| Result | Our study revealed that SM inhibited the growth of HCC and enhanced the anticancer effect of SF through HOTTIP-TUG1/miR-4726-5p/MUC1 signaling pathway. These findings will provide potential therapeutic targets and strategies for the treatment of HCC. | |||
| Pair Name | Rosmarinic acid, Anti-MUC1 antibody | |||
| Phytochemical | Rosmarinic acid | |||
| Drug | Anti-MUC1 antibody | |||
| Disease Info | [ICD-11: 2B72.Z] | Gastric cancer | Investigative | |
| Regulate Info | Up-regulation | Mucin-1 | Expression | |
| Result | Results of the study indicate that combined action of anti-MUC1 and RA is more effective than monotherapy in relation to examined cancer related factors. Such treatment can be considered as new, promising strategy in gastric cancer therapy. | |||
| Pair Name | Polyphyllin I, Enzalutamide | |||
| Phytochemical | Polyphyllin I | |||
| Drug | Enzalutamide | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Regulate Info | Down-regulation | Mucin-1 | Expression | |
| Result | Our results indicate that PPI inhibits the growth of CRPC cells by inhibiting p65 protein and concomitantly reducing HOTAIR expression, thereby suppressing MUC1 gene expression. The novel regulatory interaction of p65 and HOTAIR converge in the inhibition of MUC1 expression and overall PPI response. The combination of PPI and enzalutamide exhibits synergy. This study reveals a novel mechanism underlying the synergistic inhibitory effect of PPI and enzalutamide on the growth of CRPC cells. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway. Mol Carcinog. 2022 Apr;61(4):417-432. doi: 10.1002/mc.23389. | Click |
| 2 | Anti-cancer effect of combined action of anti-MUC1 and rosmarinic acid in AGS gastric cancer cells. Eur J Pharmacol. 2021 Jul 5;902:174119. doi: 10.1016/j.ejphar.2021.174119. | Click |
| 3 | Crosstalk of NF-κB/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment. Cell Physiol Biochem. 2018;47(2):759-773. doi: 10.1159/000490028. | Click |
